{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:16:36Z","timestamp":1740179796289,"version":"3.37.3"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>A 68-year-old woman was referred to our hospital for further evaluation of fever, nasal congestion, deafness, and multiple pulmonary nodules refractory to antibiotic use. Despite negative findings of antineutrophil cytoplasmic antibodies, she was diagnosed with granulomatosis with polyangiitis based on the analysis of biopsy specimens of pulmonary nodules. The administrations of oral prednisolone and six intravenous cyclophosphamide (IVCY) resulted in the prompt relief of symptoms and disappearance of pulmonary nodules. However, 3\u2009months after the completion of IVCY therapy, nasal congestion and deafness flared up with an increase in the C-reactive protein level; a repeat computed tomography revealed a left lung nodule. Consequently, she underwent remission induction and maintenance therapy with rituximab (RTX), which resulted in the symptomatic improvement and disappearance of pulmonary nodules after 6\u2009months. The patient remained in remission thereafter. Therefore, RTX may be an effective therapeutic option even in the absence of detectable autoantibodies.<\/jats:p>","DOI":"10.1093\/mrcr\/rxab034","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T22:14:13Z","timestamp":1634854453000},"page":"93-96","source":"Crossref","is-referenced-by-count":4,"title":["Successful rituximab treatment in a patient with ANCA-negative granulomatosis with polyangitis: A case report"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-3904","authenticated-orcid":false,"given":"Koichi","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Shin-Kokura Hospital, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shin-Kokura Hospital, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shin-Kokura Hospital, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shin-Kokura Hospital, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"2022011123195677300_R1","doi-asserted-by":"crossref","first-page":"643.e9","DOI":"10.1016\/j.amjmed.2006.08.016","article-title":"ANCA are detectable in nearly all patients with active severe Wegener\u2019s granulomatosis","volume":"120","author":"Finkielman","year":"2007","journal-title":"Am J Med"},{"key":"2022011123195677300_R2","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2022011123195677300_R3","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/art.39812","article-title":"Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener\u2019s): distinct patient subsets","volume":"68","author":"Miloslavsky","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022011123195677300_R4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2022011123195677300_R5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2022011123195677300_R6","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2022011123195677300_R7","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-1857-z","article-title":"Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial","volume":"18","author":"Gopaluni","year":"2017","journal-title":"Trials"},{"key":"2022011123195677300_R8","first-page":"2017","article-title":"Efficacy of rituximab in limited Wegener\u2019s granulomatosis with refractory granulomatous manifestations","volume":"35","author":"Seo","year":"2008","journal-title":"J Rheumatol"},{"key":"2022011123195677300_R9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/s10165-008-0119-z","article-title":"Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener\u2019s granulomatosis: a case report","volume":"19","author":"Ooka","year":"2009","journal-title":"Mod Rheumatol"},{"key":"2022011123195677300_R10","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/846063","article-title":"Successful treatment of ANCA-negative Wegener\u2019s granulomatosis with rituximab","author":"Khan","year":"2010","journal-title":"Int J Rheumatol"},{"key":"2022011123195677300_R11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000431336","article-title":"Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab","volume":"41","author":"Shah","year":"2015","journal-title":"Am J Nephrol"},{"key":"2022011123195677300_R12","article-title":"When anti-neutrophil cytoplasmic antibody fails: a case of anti-neutrophil cytoplasmic antibody negative granulomatosis with polyangiitis","volume":"12","author":"Gangireddy","year":"2020","journal-title":"Cureus"},{"key":"2022011123195677300_R13","doi-asserted-by":"publisher","DOI":"10.2174\/1573397116666200517120935.","article-title":"Fatal outcome of rituximab in an ANCA negative granulomatosis with polyangiitis patient with acute pancreatitis and pancreatic mass","author":"Alesaeidi","journal-title":"Curr Rheumatol Rev"},{"key":"2022011123195677300_R14","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1172\/JCI65292","article-title":"Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis","volume":"123","author":"Roth","year":"2013","journal-title":"J Clin Invest"},{"key":"2022011123195677300_R15","doi-asserted-by":"crossref","DOI":"10.1186\/ar2923","article-title":"T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?","volume":"12","author":"Wilde","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2022011123195677300_R16","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1002\/art.38107","article-title":"Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response","volume":"65","author":"M\u00e9let","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022011123195677300_R17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/rheumatology\/keh443","article-title":"Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab","volume":"44","author":"Tokunaga","year":"2005","journal-title":"Rheumatology"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxab034\/41818906\/rxab034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/1\/93\/42106785\/rxab034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/1\/93\/42106785\/rxab034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:47:06Z","timestamp":1642560426000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/6\/1\/93-96\/6407759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,10,22]]},"published-print":{"date-parts":[[2022,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxab034","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,10,22]]}}}